Free Trial
NASDAQ:TRML

Tourmaline Bio Q2 2024 Earnings Report

Tourmaline Bio logo
$16.30 -1.55 (-8.68%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$17.01 +0.71 (+4.35%)
As of 05/2/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.72
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Tourmaline Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tourmaline Bio Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
7:00AM ET

Earnings Documents

Tourmaline Bio Earnings Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Chardan Capital Forecasts Tourmaline Bio FY2025 Earnings
See More Tourmaline Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email.

About Tourmaline Bio

Tourmaline Bio (NASDAQ:TRML) operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

View Tourmaline Bio Profile

More Earnings Resources from MarketBeat